Hypothesis

The biphasic rise and fall of the Firmicutes/Bacteroidetes (F/B) ratio after age 70 is caused by age‑dependent loss of specific mucin O‑glycan structures that butyrate‑producing Firmicutes require for mucosal attachment, while opportunistic Proteobacteria colonize the exposed protein core.

Mechanistic Rationale

With advancing age, mucosal glycosyltransferase activity declines, leading to truncated O‑glycans on intestinal mucins. Firmicutes such as Roseburia and Faecalibacterium prausnitzii express carbohydrate‑binding modules that recognize intact core‑1 and core‑2 O‑glycans for stable niche occupancy. When these glycans are depleted, their adhesion fails, reducing their competitive advantage. Simultaneously, exposed peptide backbones of mucins become accessible to proteolytic Proteobacteria, which thrive on the liberated amino acids and trigger low‑grade LPS translocation. This shift explains the observed drop in butyrate, impaired colonocyte energy metabolism, and heightened inflammaging in the elderly. It's well established that butyrate serves as the primary energy source for colonocytes and maintains gut barrier integrity.

Testable Predictions

1. Individuals aged ≥70 will show a negative correlation between mucosal O‑glycan abundance (measured by lectin blotting or mass spectrometry) and the Firmicutes/Bacteroidetes (F/B) ratio.
2. Oral supplementation with N‑acetylglucosamine (GlcNAc), a precursor for O‑glycan synthesis, will restore mucin glycosylation, increase the relative abundance of butyrate‑producing Firmicutes, and raise fecal butyrate concentrations.
3. Improved mucin glycosylation will correlate with decreased serum LPS‑binding protein and lower IL‑6/TNF‑α levels, indicating reduced systemic inflammation.
4. Colonocyte barrier function, assessed by urinary sucralose‑mannitol ratio or FITC‑dextran permeability in ex vivo biopsies, will improve alongside microbial shifts.

Experimental Design

• Recruit a double‑blind, placebo‑controlled trial of 120 participants aged 70‑85, stratified by baseline Firmicutes/Bacteroidetes (F/B) ratio.
• Intervention: 2 g GlcNAc daily for 12 weeks; control: isocaloric maltodextrin.
• Collect stool, blood, and rectal biopsies at baseline, week 6, and week 12.
• Microbiome: 16S rRNA sequencing to compute Firmicutes/Bacteroidetes (F/B) ratio; qPCR for Roseburia and F. prausnitzii.
• Metabolomics: targeted SCFA quantification, especially butyrate.
• Mucin glycosylation: lectin array (VVA, PNA) and LC‑MS/MS O‑glycan profiling of mucus extracts.
• Inflammation: serum LPS‑BP, IL‑6, TNF‑α, CRP.
• Barrier: We'll assess barrier function using fecal zonulin, urinary sucralose‑mannitol ratio, and ex vivo Ussing chamber permeability.
• Statistical plan: mixed‑effects models testing interaction between time and group; mediation analysis to assess whether changes in mucin glycosylation mediate the effect of GlcNAc on Firmicutes/Bacteroidetes (F/B) ratio and inflammation.

Potential Implications

If GlcNAc rescues mucin O‑glycans and reverses the detrimental Firmicutes/Bacteroidetes (F/B) ratio shift, it would provide a mechanistically grounded, nutrition‑based strategy to mitigate inflammaging and colonocyte dysfunction in the oldest old. Failure to observe the predicted changes would falsify the hypothesis that mucin glycosylation drives the late‑life F/B reversal, redirecting focus to alternative drivers such as hormone‑mediated immune senescence or cumulative antibiotic exposure.